Last update 28 Jan 2026

TQB-3820

Overview

Basic Info

Drug Type
Degradable Molecular Glue
Synonyms
TQB-3820, TQB3820
Target
CRBN
Action
degraders
Mechanism
CRBN degraders(Cereblon degraders)
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [1]
Active Indication
B-cell lymphoma refractoryChronic Lymphocytic LeukemiaRelapse multiple myeloma+ [1]
Inactive Indication
Indolent B-Cell Non-Hodgkin Lymphoma
Originator Organization
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Active Organization
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with TQB-3820
NCT05020639
/ RecruitingPhase 1
A Phase I Study to Evaluate the Tolerability and Pharmacokinetics of TQB3820 in Relapsed or Refractory Multiple Myeloma (R/R MM) or Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (R/R B-NHL)
100 Clinical Results associated with TQB-3820
Login to view more data
100 Translational Medicine associated with TQB-3820
Login to view more data
100 Patents (Medical) associated with TQB-3820
Login to view more data
100 Deals associated with TQB-3820
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
B-cell lymphoma refractoryPhase 1
China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
31 Aug 2021
Chronic Lymphocytic LeukemiaPhase 1
China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
31 Aug 2021
Relapse multiple myelomaPhase 1
China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
31 Aug 2021
Indolent B-Cell Non-Hodgkin LymphomaPhase 1
China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
25 Aug 2021
Small Lymphocytic LymphomaPhase 1
China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
25 Aug 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free